Arexvy clinical trials
How each study uses arexvy is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the arexvy studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2024 (7)
| Year | Studies |
|---|---|
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 7 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 3
GlaxoSmithKline (15) · University Health Network, Toronto (1) · Johns Hopkins University (1) · Medical University of Vienna (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test arexvy.
- Apr 2027Immunogenicity of RSVPreF3 Vaccine in Immunocompromised PersonsPhase 2 · Johns Hopkins University
Studies
Open first, then newest update. How each study uses arexvy is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Immunogenicity of RSVPreF3 Vaccine in Immunocompromised PersonsRecruitingPhase 2Johns Hopkins UniversityNCT07050732Written as Arexvy (2 doses total)
- RSV Vaccination in Immunocompromised Patients.RecruitingPhase 2Medical University of ViennaNCT06597916Written as Arexvy powder and suspension for injection
- A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and OlderCompletedPhase 3GlaxoSmithKlineNCT06551181Written as RSVPreF3 OA investigational vaccine
- A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus DiseaseActive, not recruitingPhase 3GlaxoSmithKlineNCT07220109Written as RSVPreF3 OA vaccine
- RSV Vaccine in Transplant RecipientsActive, not recruitingPhase 3University Health Network, TorontoNCT06593210Written as Adjuvant, non-live RSV vaccine
- An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyActive, not recruitingPhase 3GlaxoSmithKlineNCT06534892Written as RSVPreF3 OA vaccine
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and AboveActive, not recruitingPhase 3GlaxoSmithKlineNCT04732871Written as RSVPreF3 OA investigational vaccine
- A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)CompletedPhase 3GlaxoSmithKlineNCT06614725Written as RSVPreF3 OA investigational vaccine
- A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and AboveCompletedPhase 2GlaxoSmithKlineNCT05921903Written as RSVPreF3 OA Investigational Vaccine
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT06374394Written as RSVPreF3 OA investigational vaccine
- A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and AboveCompletedPhase 3GlaxoSmithKlineNCT06389487Written as RSVPreF3 OA investigational vaccine
- Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT04886596Written as RSVPreF3 OA vaccine
- A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy AdultsCompletedPhase 3GlaxoSmithKlineNCT05966090Written as RSVPreF3 OA investigational vaccine
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and AboveCompletedPhase 3GlaxoSmithKlineNCT05590403Written as RSVPreF3 OA investigational vaccine
- A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT05559476Written as RSVPreF3 OA investigational vaccine
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT05568797Written as RSVPreF3 OA vaccine
- A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT04841577Written as RSVPreF3 OA investigational vaccine
- A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT05059301Written as RSVPreF3 OA investigational vaccine
Given beside what is tested · 2 — arexvy is usual care or a partner of the new treatment
- Vaccine Responses in Patients With B Cell MalignanciesRecruitingPhase 4National Heart, Lung, and Blood Institute (NHLBI)NCT05170399Written as AREXVY, ABRYSVO
- Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older AdultsCompletedPhase 3GlaxoSmithKlineNCT05879107Written as RSVPreF3 OA investigational vaccine
As the comparator · 4 — what is tested is compared with arexvy
- Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy AdultsRecruitingPhase 1Clover Biopharmaceuticals USA, LLCNCT06843317Written as AREXVY
- A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older AdultsActive, not recruitingPhase 1SanofiNCT06556147Written as Arexvy 120 mcg
- A Study of IVX-A12 in Adults ParticipantsCompletedPhase 2Icosavax, Inc.NCT06481579Written as Licensed RSV Vaccine
- First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy AdultsCompletedPhase 1Clover Biopharmaceuticals AUS PtyNCT06194318Written as AREXVY